Ferrara Felicetto, Palmieri Salvatore, Pocali Barbara, Pollio Filiberto, Viola Assunta, Annunziata Silvana, Sebastio Lucia, Schiavone Ettore Mariano, Mele Giuseppina, Gianfaldoni Giacomo, Leoni Franco
Hematology Division, A.O.R.N. A Cardarelli, Naples, Italy.
Eur J Haematol. 2002 Apr;68(4):203-9. doi: 10.1034/j.1600-0609.2002.01651.x.
To evaluate therapeutic results and prognostic factors from a series of 44 patients affected by de novo acute myeloid leukemia with multilineage dysplasia (MD-AML), treated with the combination of fludarabine, cytarabine and G-CSF (FLAG).
Forty-four patients with de novo MD-AML were treated with the FLAG regimen. The median age was 61 yr (range 31-75 yr). Induction therapy consisted of the FLAG regimen; consolidation included idarubicin plus cytarabine. Patients with a compatible donor and aged less than 55 yr were programmed to receive allogeneic bone marrow transplantation (BMT), while in those without a donor and aged less than 65 yr autologous transplantation with peripheral blood stem cells mobilized by a consolidation regimen plus G-CSF was planned. Bone marrow harvest was performed in poor mobilizers.
Complete remission (CR) was achieved in 28 out of 44 patients (64%). Death in induction occurred in four patients (9%), while 12 patients (27%) were resistant to FLAG. Toxicity of consolidation was negligible. Most patients aged less than 60 yr and achieving CR were eligible for transplantation procedures, the main reason of exclusion being early relapse. Median overall survival and disease free survival were 16 and 22 months, respectively. Unfavorable cytogenetics was the only parameter significantly related to inferior clinical outcome following multivariate analysis.
Multilineage dysplasia per se is not an adverse prognostic factor in AML patients treated with the FLAG regimen. Favorable results are obtained in patients with intermediate karyotype, while in those with adverse cytogenetics new approaches are clearly needed. The toxicity of the regimen is also acceptable in the elderly, and following induction/consolidation, most patients may be submitted to transplantation procedures.
评估44例初发多系发育异常急性髓系白血病(MD-AML)患者采用氟达拉滨、阿糖胞苷和粒细胞集落刺激因子(FLAG)联合治疗的疗效及预后因素。
44例初发MD-AML患者接受FLAG方案治疗。中位年龄为61岁(范围31 - 75岁)。诱导治疗采用FLAG方案;巩固治疗包括去甲氧柔红霉素加阿糖胞苷。有合适供者且年龄小于55岁的患者计划接受异基因骨髓移植(BMT),而无供者且年龄小于65岁的患者计划采用巩固方案加粒细胞集落刺激因子动员外周血干细胞进行自体移植。对动员效果差的患者进行骨髓采集。
44例患者中有28例(64%)达到完全缓解(CR)。4例患者(9%)在诱导治疗期间死亡,12例患者(27%)对FLAG耐药。巩固治疗的毒性可忽略不计。大多数年龄小于60岁且达到CR的患者符合移植条件,排除的主要原因是早期复发。中位总生存期和无病生存期分别为16个月和22个月。多因素分析显示,不良细胞遗传学是唯一与较差临床结局显著相关的参数。
对于接受FLAG方案治疗的AML患者,多系发育异常本身并非不良预后因素。核型为中间型的患者疗效良好,而核型不良的患者显然需要新的治疗方法。该方案的毒性在老年患者中也可接受,诱导/巩固治疗后,大多数患者可接受移植手术。